(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Cingulate's earnings in 2026 is -$27,714,796.On average, 7 Wall Street analysts forecast CING's earnings for 2026 to be -$29,475,424, with the lowest CING earnings forecast at -$32,916,569, and the highest CING earnings forecast at -$22,024,920. On average, 6 Wall Street analysts forecast CING's earnings for 2027 to be -$21,801,883, with the lowest CING earnings forecast at -$26,801,633, and the highest CING earnings forecast at -$17,006,584.
In 2028, CING is forecast to generate -$15,301,943 in earnings, with the lowest earnings forecast at -$15,612,602 and the highest earnings forecast at -$14,776,212.